Active Not Recruiting PHASE3 INTERVENTIONAL 4-arm NCT05156281

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib

Sponsor: Novartis Pharmaceuticals

Conditions Relapsing Multiple Sclerosis

Interventions Remibrutinib Teriflunomide

Updated 23 times since 2022 Last updated: Feb 2, 2026 Started: Dec 13, 2021 Primary completion: Apr 30, 2026 Completion: Oct 30, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Relapsing Multiple Sclerosis, this trial is ongoing. The trial is conducted by Novartis Pharmaceuticals and has accumulated 23 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

23 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE3
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE3
Sep 2025 — Nov 2025 [monthly]

Recruiting PHASE3

▶ Show 18 earlier versions

Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE3
May 2025 — Jul 2025 [monthly]

Recruiting PHASE3
Apr 2025 — May 2025 [monthly]

Recruiting PHASE3
Feb 2025 — Apr 2025 [monthly]

Recruiting PHASE3
Oct 2024 — Feb 2025 [monthly]

Recruiting PHASE3
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
May 2024 — Jul 2024 [monthly]

Recruiting PHASE3
Aug 2023 — May 2024 [monthly]

Recruiting PHASE3
Feb 2023 — Aug 2023 [monthly]

Recruiting PHASE3
Dec 2022 — Feb 2023 [monthly]

Recruiting PHASE3
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE3
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE3
May 2022 — Jul 2022 [monthly]

Recruiting PHASE3
Apr 2022 — May 2022 [monthly]

Recruiting PHASE3
Mar 2022 — Apr 2022 [monthly]

Recruiting PHASE3
Jan 2022 — Mar 2022 [monthly]

Recruiting PHASE3

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albacete, Spain , Amritsar, India , Athens, Greece , Aurora, United States , Banská Bystrica, Slovakia , Barcelona, Spain , Beijing, China , Bialystok, Poland , Bloemfontein, South Africa , Bombal, Argentina and 185 more locations